zandant Wednesday, 05/20/20 01:42:35 PM Re: loanranger post# 297832 Post # of 308033 Interesting observations. All questions that need to be answered and are significant in determining whether B will be a viable treatment - in addition to whether the drug works in actual humans. I don't know the answers but would like to find out. Assuming that "pretreatment" and "preincubation" carry the same meaning in the scientific community, on the surface, it initially appears that there is a greater benefit if the time B is applied is closer to the time of the infection - 1 hour before infection has a greater impact than 2 hours. (Not sure why they used different time measurements.). If it was applied even closer to the infection would the results have been greater? If it was applied 5 hours before the infection, what would the result have been? How long does B effectively remain in the system and how often would it have to be reintroduced? But then you have to ask if there is a distinction based on the time (how many hours after pretreatment) of measurement? Or some combination? Again, how long does B effectively remain in the system and how often would it have to be reintroduced? Not sure we have answers to those questions. If the company had an investor relations group those questions could be presented in the first instance. Looks like Leo and Jane would be the only options and the chance of Leo becoming Time's Person of the Year is probably greater than getting a reply from the company.